These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28777460)

  • 1. Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.
    Evangelisti C; Cappellini A; Oliveira M; Fragoso R; Barata JT; Bertaina A; Locatelli F; Simioni C; Neri LM; Chiarini F; Lonetti A; Buontempo F; Orsini E; Pession A; Manzoli L; Martelli AM; Evangelisti C
    J Cell Physiol; 2018 Mar; 233(3):1796-1811. PubMed ID: 28777460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K-δ inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells.
    Safaroghli-Azar A; Bashash D; Sadreazami P; Momeny M; Ghaffari SH
    Anticancer Drugs; 2017 Apr; 28(4):436-445. PubMed ID: 28125433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
    Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
    J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor.
    Guo X; Zhou CY; Li Q; Gao J; Zhu YP; Gu L; Ma ZG
    Biomed Environ Sci; 2013 May; 26(5):371-81. PubMed ID: 23611130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
    Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
    Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
    Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
    Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal.
    Xie M; Yang A; Ma J; Wu M; Xu H; Wu K; Jin Y; Xie Y
    Cell Death Dis; 2019 Jan; 9(10):1013. PubMed ID: 30598523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.
    Neri LM; Cani A; Martelli AM; Simioni C; Junghanss C; Tabellini G; Ricci F; Tazzari PL; Pagliaro P; McCubrey JA; Capitani S
    Leukemia; 2014 Apr; 28(4):739-48. PubMed ID: 23892718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.
    Bornhauser BC; Bonapace L; Lindholm D; Martinez R; Cario G; Schrappe M; Niggli FK; Schäfer BW; Bourquin JP
    Blood; 2007 Sep; 110(6):2084-91. PubMed ID: 17537996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose anisomycin sensitizes glucocorticoid-resistant T-acute lymphoblastic leukemia CEM-C1 cells to dexamethasone-induced apoptosis through activation of glucocorticoid receptor and p38-MAPK/JNK.
    Liu Y; Ge J; Li Q; Guo X; Gu L; Ma ZG; Li XH; Zhu YP
    Leuk Lymphoma; 2014 Sep; 55(9):2179-88. PubMed ID: 24597985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of autophagy overcomes glucocorticoid resistance in lymphoid malignant cells.
    Jiang L; Xu L; Xie J; Li S; Guan Y; Zhang Y; Hou Z; Guo T; Shu X; Wang C; Fan W; Si Y; Yang Y; Kang Z; Fang M; Liu Q
    Cancer Biol Ther; 2015; 16(3):466-76. PubMed ID: 25778879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.
    Simioni C; Martelli AM; Zauli G; Vitale M; McCubrey JA; Capitani S; Neri LM
    J Cell Physiol; 2018 Oct; 233(10):6440-6454. PubMed ID: 29667769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor.
    Liang YN; Tang YL; Ke ZY; Chen YQ; Luo XQ; Zhang H; Huang LB
    J Steroid Biochem Mol Biol; 2017 Sep; 172():62-68. PubMed ID: 28578002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyr3, a TRPC3 channel blocker, potentiates dexamethasone sensitivity and apoptosis in acute lymphoblastic leukemia cells by disturbing Ca(2+) signaling, mitochondrial membrane potential changes and reactive oxygen species production.
    Abdoul-Azize S; Buquet C; Vannier JP; Dubus I
    Eur J Pharmacol; 2016 Aug; 784():90-8. PubMed ID: 27179991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Puerarin attenuates glucocorticoid-induced apoptosis of hFOB1.19 cells through the JNK- and Akt-mediated mitochondrial apoptotic pathways.
    Yu D; Mu S; Zhao D; Wang G; Chen Z; Ren H; Fu Q
    Int J Mol Med; 2015 Aug; 36(2):345-54. PubMed ID: 26101183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.